We report a rare case of acute neurological Behçet’s disease (neuro-BD) diagnosed concurrently with systemic Behçet’s disease ...
PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
The MarketWatch News Department was not involved in the creation of this content. -- Study results support advancing SGX945 in this difficult-to-treat orphan disease -- Results suggest potential ...
Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...
Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...
(RTTNews) - Shares of Soligenix Inc. (SNGX) are up more than 20% at $1.50 in premarket hours, following encouraging results from its Phase 2a proof of concept study of SGX945 in the treatment of ...
PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy The Phase 2a study, evaluating control of oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results